#### BEFORE THE

# INDEPENDENT CITIZENS' OVERSIGHT COMMITTEE TO THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE ORGANIZED PURSUANT TO THE CALIFORNIA STEM CELL RESEARCH AND CURES ACT

#### SPECIAL MEETING

LOCATION:

HYATT REGENCY SAN FRANCISCO AIRPORT 1333 BAYSHORE HIGHWAY BURLINGAME, CALIFORNIA

APRIL 30, 2014 DATE:

9 A.M.

BETH C. DRAIN, CSR CSR. NO. 7152 REPORTER:

BRS FILE NO.: 96126

#### INDEX

ITEM DESCRIPTION NO.	PAGE
OPEN SESSION	
1. CALL TO ORDER.	3
2. PLEDGE OF ALLEGIANCE.	3
3. ROLL CALL.	3
CLOSED SESSION	
4. DISCUSSION OF PERSONNEL [PRESIDENTIAL SEARCH] (GOVERNMENT CODE SECTION 11126, SUBDIVISION (A); HEALTH & SAFETY CODE SECTION 125290.30(F) (3) (D)).	4
OPEN SESSION	
5. CONSIDERATION OF APPOINTMENT OF NEW PRESIDENT, INCLUDING COMPENSATION PACKAGE.	6
6. PUBLIC COMMENT	

1	APRIL 30, 2014; 9 A.M.
2	
3	CHAIRMAN THOMAS: MARIA, WILL YOU PLEASE
4	LEAD US IN THE ALLEGIANCE AND THEN CALL THE ROLL.
5	THANK YOU.
6	(THE PLEDGE OF ALLEGIANCE.)
7	CHAIRMAN THOMAS: ROLL CALL, PLEASE.
8	MS. BONNEVILLE: DAVID BRENNER. SUE
9	BRYANT. LARS BERGLUND.
10	DR. BERGLUND: YES.
11	MS. BONNEVILLE: ANNE-MARIE DULIEGE.
12	ELIZABETH FINI. MICHAEL FRIEDMAN.
13	DR. FRIEDMAN: HERE.
14	MS. BONNEVILLE: JUDY GASSON.
15	DR. GASSON: HERE.
16	MS. BONNEVILLE: SAM HAWGOOD. STEVE
17	JUELSGAARD.
18	DR. JUELSGAARD: HERE.
19	MS. BONNEVILLE: BERT LUBIN.
20	DR. LUBIN: HERE.
21	MS. BONNEVILLE: SHLOMO MELMED. LLOYD
22	MI NOR.
23	DR. MINOR: HERE.
24	MS. BONNEVILLE: JOE PANETTA.
25	MR. PANETTA: HERE.
	3

ı	
1	MS. BONNEVILLE: FRANCISCO PRIETO.
2	DR. PRI ETO: HERE.
3	MS. BONNEVILLE: ROBERT QUINT.
4	DR. QUINT: HERE.
5	MS. BONNEVILLE: AL ROWLETT.
6	MR. ROWLETT: HERE.
7	MS. BONNEVILLE: JOAN SAMUELSON. JEFF
8	SHEEHY.
9	MR. SHEEHY: HERE.
10	MS. BONNEVILLE: OS STEWARD.
11	DR. STEWARD: HERE.
12	MS. BONNEVILLE: JONATHAN THOMAS.
13	CHAIRMAN THOMAS: HERE.
14	MS. BONNEVILLE: ART TORRES. CHRISTINA
15	VUORI.
16	DR. VUORI: HERE.
17	MS. BONNEVILLE: DONNA WESTON.
18	DR. WESTON: HERE.
19	MS. BONNEVILLE: DIANE WINOKUR.
20	MS. WINOKUR: HERE.
21	CHAIRMAN THOMAS: I'D LIKE TO THANK
22	EVERYBODY FOR COMING THIS MORNING. AS YOU KNOW,
23	TODAY IS THE CULMINATION OF A MULTIPLE MONTH PROCESS
24	THAT WE'VE HAD TO IDENTIFY AND SELECT A NEW
25	PRESIDENT FOR CIRM TO REPLACE DR. TROUNSON, WHO WILL
	4
	4

1	BE RETURNING TO AUSTRALIA FOR THE NEXT CHAPTER IN
2	HIS PROFESSIONAL AND PERSONAL LIFE, GETTING BACK TO
3	HIS FAMILY.
4	WHAT WE'RE GOING TO DO TODAY IS WE'RE
5	GOING TO ADJOURN HERE IN A MINUTE INTO CLOSED
6	SESSION, AND THEN WE WILL HAVE A DISCUSSION ABOUT
7	THE CANDIDATES, ETC. AND WE WILL AND THIS IS FOR
8	THE BENEFIT OF THOSE MEMBERS OF THE PUBLIC WHO ARE
9	IN THE ROOM. THIS WILL BE A PROCESS THAT IS GOING
10	TO TAKE A LITTLE WHILE. EVERYBODY CAN APPRECIATE.
11	AT THE END OF THE DISCUSSION, WE WILL RECONVENE IN
12	PUBLIC SESSION TO REPORT ANY RESULTS THAT HAVE COME
13	OUT OF CLOSED SESSION AND THEN TAKE IT FROM THERE.
14	SO I GUESS WITHOUT FURTHER ADO, JAMES,
15	COULD YOU STIPULATE THE RELEVANT SECTION THAT WE ARE
16	USING TO ADJOURN INTO CLOSED SESSION.
17	MR. HARRISON: YES. THE BOARD WILL BE
18	CONVENING IN CLOSED SESSION TO DISCUSS PERSONNEL
19	PURSUANT TO GOVERNMENT CODE SECTION 11126 AND HEALTH
20	AND SAFETY CODE SECTION 125290.30(F)(3)(D).
21	CHAIRMAN THOMAS: THANK YOU, JAMES. SO
22	MEMBERS OF THE PUBLIC, IF YOU'D BE SO KIND AS TO
23	ADJOURN FROM THE ROOM HERE FOR A WHILE, AND WE WILL
24	NOTIFY YOU WHEN OPEN SESSION RECONVENES IN A BIT.
25	THANK YOU VERY MUCH.
	_
	5

1	MS. BONNEVILLE: FOR THOSE OF YOU ON THE
2	PHONE, BOARD MEMBERS, IF YOU COULD HANG UP AND
3	REDIAL INTO THE CLOSED SESSION NUMBER. THANKS.
4	(THE BOARD THEN RECONVENED IN CLOSED
5	SESSION, NOT REPORTED, NOR HEREIN TRANSCRIBED. AT
6	THE CONCLUSION OF CLOSED SESSION, THE BOARD
7	RECONVENED IN OPEN SESSION AND WAS HEARD AS
8	FOLLOWS: )
9	CHAIRMAN THOMAS: OKAY. I'D LIKE TO CALL
10	THIS MEETING BACK TO ORDER IN OPEN SESSION. AS WE
11	SAID EARLIER THIS MORNING, THE BOARD TODAY IS AT THE
12	FINAL STAGE OF SELECTING A NEW PRESIDENT FOR CIRM.
13	IT COMES AT A TIME WHEN CIRM'S PORTFOLIO IN THE
14	SPACE OF CELLULAR THERAPY AND REGENERATIVE MEDICINE
15	IS SECOND TO NONE. WE'VE HAD TREMENDOUS GROWTH OVER
16	THE PAST TEN YEARS IN TERMS OF FUNDING RESEARCH
17	CURRENTLY IN 39 INCURABLE DISEASES AND CONDITIONS,
18	HAVING FUNDED SOME 65 EITHER MEDICAL SCHOOLS,
19	RESEARCH INSTITUTIONS, OR BIOTECH COMPANIES
20	THROUGHOUT THE STATE OF CALIFORNIA, ALL OF WHICH,
21	THROUGH THE WISDOM OF THE VOTERS OF CALIFORNIA, HAS
22	TRANSFORMED THE STATE INTO THE EPICENTER OF STEM
23	CELL RESEARCH IN THE WORLD.
24	WE NOW REACH A TIME IN OUR CIRM LIFE,
25	WHICH IS SORT OF MIDLIFE, WHERE THE BOARD, AFTER

1	CONSIDERABLE DISCUSSION, HAS DETERMINED THAT WE
2	WANTED TO PLACE INCREASING EMPHASIS ON PROJECT
3	DEVELOPMENT, GETTING OUR MANY DIFFERENT ELEMENTS OF
4	OUR TRANSLATIONAL PORTFOLIO THROUGH CLINICAL TRIALS
5	TOWARDS PROOF OF CONCEPT IN AS PRUDENT AND
6	EXPEDITIOUS A MANNER AS POSSIBLE.
7	AS A RESULT, WHEN WE WENT OUT NOW SEVERAL
8	MONTHS AGO TO ADVERTISE FOR THE POSITION OF
9	PRESIDENT, WE MADE IT CLEAR IN THE CRITERIA THAT
10	WERE LISTED ON THE WEBSITE THAT WE WERE LOOKING FOR
11	SOMEBODY WHO HAD A COMBINATION OF THE FOLLOWING
12	CRITERIA: FAMILIARITY WITH THE STEM CELL SPACE,
13	SOMEBODY WITH A LONG TRACK RECORD OF MANAGEMENT
14	EXPERIENCE IN BIOTECH, IDEALLY SOMEBODY WHO IS
15	FAMILIAR WITH US AND WE WITH HIM OR HER, SOMEBODY
16	WHO HAD A GREAT DEAL OF HANDS-ON EXPERIENCE WITH THE
17	CLINICAL TRIAL PROCESS, LIKEWISE WITH THE REGULATORY
18	PROCESS AND ALL THAT GOES INTO IT, PARTICULARLY IN
19	THE FIELD OF CELLULAR THERAPY WHERE IT'S BEEN A
20	PROCESS OF EDUCATING THE REGULATORS ON THIS NEW AND
21	EMERGING TECHNOLOGY, WANTED SOMEBODY WHO HAD
22	EXPERIENCE IN RAISING CAPITAL FOR HIS OR HER
23	ENTERPRISE WHICH WOULD BE ABLE TO BE BROUGHT TO BEAR
24	HERE TO ASSIST ME AND OUR TEAM IN GOING OUT TO RAISE
25	ALTERNATIVE FUNDS FOR THE AGENCY, AND SOMEBODY WHO
	7
	,


1	COULD COME IN AND SORT OF TAKE A FRESH LOOK, TAKE
2	STOCK OF WHAT WE HAVE HERE AT CIRM, OUR MANY
3	WONDERFUL PROGRAMS, OUR EXTRAORDINARY PORTFOLIO,
4	COME AND EVALUATE WHAT WE'RE DOING RIGHT, WHAT WE'RE
5	DOING THAT COULD BENEFIT FROM SOME ADJUSTMENT, AND
6	TO GUIDE CIRM IN THIS MIDLIFE, MORE DEVELOPMENTAL
7	PHASE INTO THE NEXT GREAT STEP.
8	OBVIOUSLY THE PERSON COMING IN SUCCEEDING
9	DR. ALAN TROUNSON, WHO OVER THE PAST SIX YEARS HAS
10	PRESIDED OVER THIS EFFORT AND HAS LED US TO THE
11	POINT WE ARE AT WITH OUR 90 SOME ODD PROJECTS IN OUR
12	TRANSLATIONAL PORTFOLIO, HAS KEPT CIRM ALWAYS ON THE
13	CUTTING-EDGE IN THE REGENERATIVE MEDICINE SPACE, AND
14	HAS POSITIONED US TO BE WORLD LEADERS IN THAT SPACE
15	FOR WHICH WE THANK HIM FOR HIS MANY CONTRIBUTIONS IN
16	GETTING US TO THE POSITION THAT WE ARE TODAY.
17	HAVING SAID ALL OF THAT, NOW IT IS MY
18	PLEASURE TO INTRODUCE THE PERSON WHO HAS COME
19	THROUGH OUR PROCESS, WHICH WAS AN EXTENSIVE ONE,
20	WHERE WE GARNERED CONSIDERABLE INTEREST FROM MANY
21	CANDIDATES THROUGH THE AID OF KORN FERRY, A
22	PREEMINENT SEARCH FIRM WHO HELPED US IN THIS REGARD,
23	WE CAME WITH A SLATE WHICH KORN FERRY AND MEMBERS OF
24	THE PRESIDENTIAL SEARCH SUBCOMMITTEE, WHOM I
25	CONVENED BACK LAST OCTOBER, WHITTLED DOWN TO SEVEN
	Ω
	. ×

1	THAT WERE INTERVIEWED IN OBVIOUSLY CLOSED SESSION,
2	CONFIDENTIAL SESSION, A COUPLE OF WEEKS AGO. WE
3	AROSE FROM THAT WITH A CONSENSUS THAT ONE CANDIDATE
4	ROSE ABOVE ALL ELSE AND WOULD BE ABLE TO TAKE CIRM
5	FROM THE CONSIDERABLE POSITION WE ARE IN
6	REGENERATIVE MEDICINE TODAY ON TO OUR NEXT BIGGER
7	AND GREATER PHASE.
8	THAT PERSON I'M HAPPY NOW TO INTRODUCE TO
9	THE PUBLIC, AND HE IS RANDY MILLS. RANDY, COULD YOU
10	COME UP TO THE PODIUM, PLEASE? RANDY IS A PERSON
11	WELL-KNOWN TO CIRM, HAVING SERVED FOR FIVE YEARS AS
12	A FREQUENT MEMBER OF OUR GRANTS WORKING GROUP. WE
13	ARE KNOWN TO HIM AS HE IS KNOWN TO US. RANDY WAS
14	MOST RECENTLY TEN YEARS THE CEO OF OSIRIS
15	THERAPEUTICS, A LEADING STEM CELL PRODUCT COMPANY
16	THAT HAS GROWN UNDER HIS LEADERSHIP FROM A SMALL
17	COMPANY TEN YEARS AGO TO ONE THAT WAS VERY
18	SUCCESSFUL IN THE SPACE.
19	HE BRINGS WITH HIM GREAT MANAGEMENT
20	EXPERTISE, GREAT KNOWLEDGE OF THE STEM CELL WORLD,
21	MUCH HANDS-ON EXPERIENCE IN CLINICAL TRIALS THROUGH
22	OSIRIS, MANY, MANY, MANY HOURS OF DEALINGS WITH
23	REGULATORY AGENCIES BOTH IN THE UNITED STATES,
24	CANADA, AND NEW ZEALAND. RANDY IS SOMEBODY WHO
25	RAISED SOME \$160 MILLION IN THE CAPITAL MARKET FOR
	ο

1	OSIRIS, VERY FAMILIAR WITH THE INVESTOR SPACE, AND
2	IS SOMEBODY WHO I THINK WILL BE THE PERFECT CHOICE
3	TO LEAD CIRM IN ITS MIDLIFE NEW CAPACITY TO WHERE WE
4	WANT TO GO.
5	HE'LL BRING A FRESH SET OF EYES, WILL BE
6	ABLE TO HELP WORK WITH OUR WONDERFUL STAFF ON
7	DIRECTION GOING FORWARD, WHAT TO EMPHASIZE, WHAT
8	NOT, ETC. WE COULD NOT BE HAPPIER TO MAKE THIS
9	CHOICE. AND SO WITHOUT FURTHER ADO, LET ME TURN IT
10	OVER TO RANDY FOR A FEW COMMENTS.
11	DR. MILLS: THANK YOU. THANK YOU VERY
12	MUCH, JON, FOR THOSE INCREDIBLY KIND WORDS. USUALLY
13	I WOULD SAY SOMETHING FUNNY RIGHT NOW, BUT I CAN'T
14	THINK OF ANYTHING. SO I'M GOING TO GO WITH SINCERE.
15	I AM SO INCREDIBLY HONORED TO BE SELECTED TO BE THE
16	NEXT LEADER OF CIRM, OF THIS INCREDIBLE
17	ORGANIZATION, OF THIS INCREDIBLE VISION, THIS
18	INCREDIBLE THOUGHT, THIS INCREDIBLE CONCEPT TO SAY
19	ABOVE NOT JUST ANY OTHER STATE, BUT LITERALLY ANY
20	OTHER COUNTRY, CALIFORNIA IS GOING TO TAKE THE LEAD
21	IN REGENERATIVE MEDICINE AND SHOW THE REST OF THE
22	WORLD THE TYPE OF POTENTIAL TO IMPACT FAVORABLY ON
23	PATIENT'S LIVES THAT CELL THERAPY AND REGENERATIVE
24	MEDICINE HAS. AND I JUST WANT TO THANK EVERYONE
25	INVOLVED IN THE SELECTION PROCESS. IT'S AN
	10

1	INCREDIBLE HONOR. I LOOK FORWARD TO DOING IT. IT'S
2	GOING TO BE A CHALLENGE.
3	I AM A REALLY BIG BELIEVER IN WELL DONE IS
4	BETTER THAN WELL SET. AND SO WE'RE GOING TO WORK ON
5	THAT, AND WE'RE GOING TO WORK REALLY HARD. AND THE
6	PROMISE I MADE TO YOU, TO THE ENTIRE BOARD AND TO
7	THE PEOPLE OF CALIFORNIA, IS THAT WE ARE GOING TO
8	WORK RELENTLESSLY FOR THE BENEFIT OF THE PATIENTS
9	AND THE PEOPLE OF THE STATE OF CALIFORNIA. THANK
10	YOU.
11	(APPLAUSE.)
12	CHAIRMAN THOMAS: THANK YOU. THANK YOU
13	VERY MUCH, RANDY. MR. SENATOR, DO YOU HAVE A
14	MOTION?
15	MR. TORRES: I WILL DEFER TO MR.
16	JUELSGAARD AND I'LL SECOND HIS MOTION ONCE HE'S MADE
17	IT.
18	DR. JUELSGAARD: I'D LIKE TO MOVE THAT C.
19	RANDALL MILLS BE APPOINTED AS PRESIDENT OF THE
20	CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE.
21	MR. TORRES: I SECOND THAT MOTION.
22	CHAIRMAN THOMAS: WE NEED TO IT'S BEEN
23	MOVED AND SECONDED. WE NEED TO HAVE JAMES LAY OUT
24	THE COMPENSATION PACKAGE AND HAVE THAT INCORPORATED
25	INTO THE MOTION AS WELL. JAMES.

1	MR. HARRISON: THE COMPENSATION TERMS FOR
2	THE APPOINTMENT OF DR. MILLS AS PRESIDENT AND CHIEF
3	EXECUTIVE OFFICER OF CIRM ARE AS FOLLOWS: HIS START
4	DATE WILL BE NEGOTIATED BETWEEN DR. MILLS AND CHAIR
5	THOMAS. AS SOME OF YOU KNOW, THE SALARY RANGE FOR
6	PRESIDENT OF CIRM IS CURRENTLY \$303,761 TO \$575,446.
7	AND DR. MILLS WILL BE APPOINTED AT A SALARY OF
8	\$550,000 ANNUALLY. CIRM WILL REIMBURSE DR. MILLS
9	FOR MOVING EXPENSES AND TEMPORARY HOUSING AS
10	PROVIDED FOR UNDER STATE LAW. HE WILL BE ENTITLED
11	TO A RELOCATION ALLOWANCE UNDER CIRM POLICY OF
12	\$75,000 PAYABLE OVER A FOUR-YEAR PERIOD, 40 PER
13	CENT
14	(THE AUDIO PORTION OF THE MEETING WAS
15	INTERRUPTED BY A POWER FAILURE AND NOT REINSTATED.
16	THE FOLLOWING IS PROVIDED TO COMPLETE THE RECORD:)
17	"MR. HARRISON CONTINUED TO OUTLINE THE
18	TERMS OF DR. MILLS' APPOINTMENT FOLLOWING THE POWER
19	FAILURE. THESE TERMS ARE REFLECTED IN THE BOARD'S
20	MINUTES. MR. JUELSGAARD THEN MADE A MOTION,
21	SECONDED BY MR. TORRES, TO APPOINT DR. MILLS AS CIRM
22	PRESIDENT AND CEO ON THE TERMS RECITED BY MR.
23	HARRISON. AFTER PUBLIC COMMENT, THE BOARD
24	UNANIMOUSLY APPROVED THE MOTION AND THE MEETING WAS
25	ADJOURNED. "
	10



#### REPORTER'S CERTIFICATE

I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT THE FOREGOING TRANSCRIPT OF THE PROCEEDINGS BEFORE THE INDEPENDENT CITIZEN'S OVERSIGHT COMMITTEE OF THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE IN THE MATTER OF ITS SPECIAL MEETING HELD AT THE LOCATION INDICATED BELOW

HYATT REGENCY SAN FRANCISCO AIRPORT 1333 BAYSHORE HIGHWAY BURLINGAME, CALIFORNIA ON APRIL 30, 2014

WAS HELD AS HEREIN APPEARS AND THAT THIS IS THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE STATEMENTS THAT APPEAR IN THIS WERE TRANSCRIBED BY ME. I ALSO CERTIFY THAT THIS TRANSCRIPT IS A TRUE AND ACCURATE RECORD OF THE PROCEEDING.

main

BETH C. DRAIN, CSR 7152

BARRISTERS' RÉPORTING SERVICE

160 S. OLD SPRINGS ROAD

SUITE 270

ANAHEIM, CALIFORNIA

(714) 444-4100